Note
Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: A study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10

https://doi.org/10.1016/j.ijpharm.2009.05.044Get rights and content

Abstract

The kinetic impact of intestinal glucuronidation metabolism on oral bioavailability (F) was assessed using reported human data of raloxifene, of which oral bioavailability was only 2%. Kinetic analysis showed that presystemic intestinal availability (Fpg) was 5.4%, whereas fraction absorbed (Ff) and hepatic availability (Fh) were 63% and 59.3%, respectively. Thus, Fpg was the lowest among factors, which affect oral bioavailability. In addition, Fpg was much lower than Fh, suggesting that intestinal glucuronidation metabolism has a greater impact on oral bioavailability than hepatic glucuronidation metabolism. It has been reported that UDP-glucuronosyltransferase (UGT) 1A1, UGT1A8, UGT1A9, and UGT1A10 are enzymes for raloxifene glucuronidation, and UGT1A8 and UGT1A10 are absent in the human liver, whereas UGT1A1, UGT1A8, UGT1A9, and UGT1A10 are present in the human intestine. Therefore, it is also suggested that intestinal glucuronidation catalyzed by UGTs, particularly UGT1A8 and UGT1A10, may play important roles in the first-pass metabolism, causing low oral bioavailability.

References (10)

There are more references available in the full text version of this article.

Cited by (85)

  • Factors Affecting Drug Absorption and Disposition

    2023, Pharmaceutics: Basic Principles and Application to Pharmacy Practice, Second Edition
  • Interaction between apigenin and sodium deoxycholate with raloxifene: A potential risk for clinical practice

    2021, European Journal of Pharmaceutical Sciences
    Citation Excerpt :

    After intravenous application raloxifene concentrations were measurable in all four groups, though significant deviation in each time point was detected. This is in correlation with previous research where significant interindividual variability in raloxifene pharmacokinetics was obtained (Kosaka et al., 2011; Lindstrom et al., 1984; Mizuma, 2009; Morello et al., 2003; Jha et al., 2011; Snyder et al., 2000). Pharmacokinetic interactions between API and NaDC, used in pretreatment, and raloxifene were evident after intravenous application of raloxifene.

  • Biopharmaceutical properties of natural products

    2021, Mitochondrial Physiology and Vegetal Molecules: Therapeutic Potential of Natural Compounds on Mitochondrial Health
View all citing articles on Scopus
View full text